News See the latest press releases about Pentixapharm. Phillip Eckert 11/12/24 Phillip Eckert 11/12/24 Pentixapharm Releases Interim Report for the Third Quarter of 2024 Read More Phillip Eckert 11/4/24 Phillip Eckert 11/4/24 Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals Read More Phillip Eckert 10/29/24 Phillip Eckert 10/29/24 Pentixapharm Holding AG: US National Cancer Institute Starts Advanced Clinical Trial with PentixaFor Read More Phillip Eckert 10/28/24 Phillip Eckert 10/28/24 Nuclear Medicine Specialist Ken Herrmann Joins Supervisory Board of Pentixapharm Holding AG Read More Phillip Eckert 10/25/24 Phillip Eckert 10/25/24 Pentixapharm Holding AG: Upcoming Changes in the Management and Supervisory Boards of the Pentixapharm Group Read More Phillip Eckert 10/19/24 Phillip Eckert 10/19/24 Pentixapharm’s CXCR4 Core Compound Subject of 17 Abstract Presentations at the Hamburg European Association of Nuclear Medicine (EANM) Read More Ad-hoc announcement Phillip Eckert 10/18/24 Ad-hoc announcement Phillip Eckert 10/18/24 EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor Read More Phillip Eckert 10/3/24 Phillip Eckert 10/3/24 Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange Read More Ad-hoc announcement Phillip Eckert 10/1/24 Ad-hoc announcement Phillip Eckert 10/1/24 Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed Read More Phillip Eckert 9/23/24 Phillip Eckert 9/23/24 Pentixapharm Holding AG Sets Price Range for Planned IPO Read More Phillip Eckert 9/12/24 Phillip Eckert 9/12/24 Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange Read More Phillip Eckert 8/26/24 Phillip Eckert 8/26/24 Pentixapharm AG Receives Orphan Drug Designation for its Radiodiagnostic Tracer PentixaFor in Marginal Zone Lymphoma by the European Medicines Agency Read More Phillip Eckert 7/3/24 Phillip Eckert 7/3/24 Pentixapharm Acquires Target Discovery Business of Glycotope Read More Phillip Eckert 7/1/24 Phillip Eckert 7/1/24 Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler Read More Phillip Eckert 6/25/24 Phillip Eckert 6/25/24 Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism Read More Phillip Eckert 11/22/23 Phillip Eckert 11/22/23 First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium-90 Anditixafortide (PentixaTher) Read More Phillip Eckert 9/11/23 Phillip Eckert 9/11/23 EANM 2023: The theranostics future is now: Innovative diagnostic application and therapeutic potential of CXCR4 Read More Phillip Eckert 6/8/23 Phillip Eckert 6/8/23 PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma Read More Phillip Eckert 2/1/23 Phillip Eckert 2/1/23 Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting Read More Phillip Eckert 11/25/22 Phillip Eckert 11/25/22 Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR Read More Newer Posts Older Posts
Phillip Eckert 11/12/24 Phillip Eckert 11/12/24 Pentixapharm Releases Interim Report for the Third Quarter of 2024 Read More
Phillip Eckert 11/4/24 Phillip Eckert 11/4/24 Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals Read More
Phillip Eckert 10/29/24 Phillip Eckert 10/29/24 Pentixapharm Holding AG: US National Cancer Institute Starts Advanced Clinical Trial with PentixaFor Read More
Phillip Eckert 10/28/24 Phillip Eckert 10/28/24 Nuclear Medicine Specialist Ken Herrmann Joins Supervisory Board of Pentixapharm Holding AG Read More
Phillip Eckert 10/25/24 Phillip Eckert 10/25/24 Pentixapharm Holding AG: Upcoming Changes in the Management and Supervisory Boards of the Pentixapharm Group Read More
Phillip Eckert 10/19/24 Phillip Eckert 10/19/24 Pentixapharm’s CXCR4 Core Compound Subject of 17 Abstract Presentations at the Hamburg European Association of Nuclear Medicine (EANM) Read More
Ad-hoc announcement Phillip Eckert 10/18/24 Ad-hoc announcement Phillip Eckert 10/18/24 EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor Read More
Phillip Eckert 10/3/24 Phillip Eckert 10/3/24 Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange Read More
Ad-hoc announcement Phillip Eckert 10/1/24 Ad-hoc announcement Phillip Eckert 10/1/24 Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed Read More
Phillip Eckert 9/23/24 Phillip Eckert 9/23/24 Pentixapharm Holding AG Sets Price Range for Planned IPO Read More
Phillip Eckert 9/12/24 Phillip Eckert 9/12/24 Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange Read More
Phillip Eckert 8/26/24 Phillip Eckert 8/26/24 Pentixapharm AG Receives Orphan Drug Designation for its Radiodiagnostic Tracer PentixaFor in Marginal Zone Lymphoma by the European Medicines Agency Read More
Phillip Eckert 7/3/24 Phillip Eckert 7/3/24 Pentixapharm Acquires Target Discovery Business of Glycotope Read More
Phillip Eckert 7/1/24 Phillip Eckert 7/1/24 Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler Read More
Phillip Eckert 6/25/24 Phillip Eckert 6/25/24 Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism Read More
Phillip Eckert 11/22/23 Phillip Eckert 11/22/23 First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium-90 Anditixafortide (PentixaTher) Read More
Phillip Eckert 9/11/23 Phillip Eckert 9/11/23 EANM 2023: The theranostics future is now: Innovative diagnostic application and therapeutic potential of CXCR4 Read More
Phillip Eckert 6/8/23 Phillip Eckert 6/8/23 PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma Read More
Phillip Eckert 2/1/23 Phillip Eckert 2/1/23 Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting Read More
Phillip Eckert 11/25/22 Phillip Eckert 11/25/22 Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR Read More
